Autonomix Medical Presents Nerve Technology at CIRSE 2026
The Woodlands, Texas, USA, September 1, 2026 Autonomix Medical, Inc. announced that two scientific abstracts featuring its transvascular nerve-targeting...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
The Woodlands, Texas, USA, September 1, 2026 Autonomix Medical, Inc. announced that two scientific abstracts featuring its transvascular nerve-targeting...
Valby, Denmark, September 3, 2026 H. Lundbeck A/S will present new mechanistic and clinical research on bexicaserin (LP352) at...
VALBY, Denmark, July 20, 2026 H. Lundbeck A/S has reached a major clinical development milestone with the last patient...
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics has unveiled encouraging late-breaking Phase IIa clinical results for its investigational immunotherapy...
